Drug Farm Receives FDA Fast Track for ROSAH Syndrome Drug

DF-003, a first-in-class ALPK1 inhibitor, granted designation to accelerate development for rare autoimmune disease.

Jan. 27, 2026 at 11:47am

Got story updates? Submit your updates here. ›

Drug Farm, a biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to DF-003, its investigational ALPK1 inhibitor, for the treatment of ROSAH syndrome. ROSAH is a rare, autosomal dominant autoinflammatory disease with no approved therapies. The Fast Track designation is designed to facilitate development and expedite review of drugs for serious or life-threatening conditions with unmet medical needs.

Why it matters

ROSAH syndrome is a debilitating disease that causes progressive vision loss, optic nerve and retinal damage, and systemic inflammation, with no current treatment options. The FDA's Fast Track designation for DF-003 recognizes the urgent need for targeted therapies and supports Drug Farm's efforts to accelerate the development of this potential first-in-class treatment.

The details

DF-003 is a novel, orally administered small-molecule inhibitor that selectively targets the disease-causing ALPK1 mutation associated with ROSAH syndrome. Preclinical studies have shown DF-003 can cross the blood-retina and blood-brain barriers and significantly suppress inflammatory markers in a mouse model of the disease. DF-003 has now entered a Phase 1b clinical trial in ROSAH syndrome patients to evaluate safety, pharmacokinetics, pharmacodynamics, and efficacy.

  • Drug Farm announced the FDA Fast Track designation on January 27, 2026.
  • DF-003 has completed a Phase 1 clinical trial in healthy volunteers and is now in a Phase 1b trial in ROSAH syndrome patients.

The players

Drug Farm

A private, clinical-stage biopharmaceutical company developing innovative treatments targeting innate immunity for hepatitis B, heart and kidney diseases, and ROSAH syndrome.

DF-003

Drug Farm's investigational, first-in-class ALPK1 inhibitor that is being developed for the treatment of ROSAH syndrome.

U.S. Food and Drug Administration (FDA)

The federal agency responsible for regulating and supervising the safety of food, drugs, and other products in the United States.

Dr. John Grigg

Professor of Clinical and Experimental Ophthalmology at the Save Sight Institute Faculty of Medicine and Health at The University of Sydney.

Henri Lichenstein, Ph.D.

Chief Executive Officer of Drug Farm.

Got photos? Submit your photos here. ›

What they’re saying

“We have designed DF-003 to directly target the genetic root cause of ROSAH syndrome.”

— Henri Lichenstein, Ph.D., Chief Executive Officer of Drug Farm

“I am encouraged by the progress of DF-003 and the FDA's decision to grant Fast Track designation. Patients with ROSAH syndrome currently have no approved treatment options, and therapies that can modify disease progression have the potential to meaningfully preserve vision and improve quality of life.”

— Dr. John Grigg, Professor of Clinical and Experimental Ophthalmology, Save Sight Institute Faculty of Medicine and Health at The University of Sydney

What’s next

Clinical data from the ongoing Phase 1b trial of DF-003 in ROSAH syndrome patients will be reported at medical meetings in 2026.

The takeaway

The FDA's Fast Track designation for DF-003 highlights the urgent need for new treatments for the rare and debilitating ROSAH syndrome, and supports Drug Farm's efforts to accelerate the development of this potential first-in-class therapy to help preserve vision and improve quality of life for patients.